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1. INTRODUCTION 
1.1. The sympathetic nervous system and cardiovascular diseases 
 
CV diseases are the leading causes of death almost all over the world. Increased SNA is 
associated with higher CV risk. 
   The SNS has an important role in the pathogenesis not only of HT and DM, but also of the 
metabolic syndrome, congestive heart failure, and renal insufficiency. It is the main 
regulatory element for the CV system. Neurons located in the RVLM of the brain stem play 
the central role for SNA. These neurons have a basic, so called tonic SNA that maintains a 
basic peripheral vascular tone. The SNA generated in the brain stem is modulated by arterial 
baroreceptors, cardiopulmonary mechanoreceptors, chemoreceptors, and more centrally by 
limbic centers, the hypothalamus and the cerebral cortex (1). The effects of SNA are 
summarized in Figure 1. 
 
Figure 1 The effects of sympathetic activation (2). 
 
 
 
 
 
 
 
 
 
 
 
 
1.2. The epidemiology of hypertension 
 
HT is one of the most important CV risk factors and it is can be controlled. The newer 
classifications of HT try to describe both its complex and progressive modality. According to 
10 
 
these newer concepts HT is a syndrome involving discrete BP thresholds, the assessment of 
an individual's risk for CV events and the TODs (3). There is a linear association between the 
BP values and CV risk and the risk of CV diseases doubles with each increment of 20/10 
mmHg, beginning at 115/75 mmHg (4). Individuals who are normotensive at 65 years of age 
and their expected residual lifetime is 20 years have a 100% risk for developing HT (5). HT is 
more prevalent in developed countries; in European countries the prevalence is around 44%, 
and in North-American countries 28% (6). HT is more common in economically developed 
countries (37.3%) compared to developing ones (22.9%) (7). Overall the prevalence of HT is 
about 30–45% of the general population (8). The prevalence of HT in Hungary, according to 
Sonkodi et al. is approximately 25.7% (9). The estimated total number of HT patients in 2000 
was 972 million, and the prognosis is an increase by 60% to a total number of 1.56 billion by 
2025. About 29% of the worldwide adult population will be affected. HT therefore poses 
great public health and economical challenges worldwide. 
 
 
1.3. The role of the sympathetic nervous system in the pathogenesis of hypertension 
 
The pathogenesis of HT is of highly sophisticated complexity, but increased SNA plays a 
major role. There are many mechanisms related to SNA that may lead to HT not only 
peripheral resistance and heart rate (Figure 2).  
 
Figure 2 Mechanisms that lead to sympathetic overactivity and hypertension. 
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1.3.1. The sympathetic and parasympathetic regulation of blood pressure 
 
The RVLM located in the brain stem is the center for the neuronal regulation of BP and HR. 
There is a sympathico-excitatory group of neurons (the so called C1 neurons) in the RVLM 
about 1 mm below the surface of the brain stem. This group of neurons is an integral part of 
baroreflex pathway. Cranial nerve IX (the glossopharyngeal nerve) carries afferent impulses 
from the aortic arch and cranial nerve X (the vagus nerve) does the same from the carotid 
sinus, baroreceptors are located there. The left nerve X also carries afferent signals from the 
mechanoreceptors in the left atrial wall (10). The stimulus for baroreceptor activity is the 
distension of the arterial wall. The afferent impulses from baroreceptors activate the NTS 
which inhibits the C1 neurons and activates inhibitory A1 neurons located in the caudal 
ventrolateral medulla (the so called depressor region). The final result of this is a 
parasympathetic activation and a decrease of tonic SNA. Efferent fibres lead from the C1 
neurons into the preganglionic sympathetic neurons located in the intermediolateral column of 
the thoracic spinal cord. Discharge of these C1 neurons increases systemic SNA (11). An 
activation of the C1 neurons elevates the BP, whereas its deactivation decreases the BP (12, 
13) (Figure 3). 
 
Figure 3 The baroreflex mechanism. 
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   The SNS modulates the heart rate (via β1-receptors) and resistance vessels (via α1-
receptors) positively. The parasympathetic nervous system mainly affects the heart rate 
negatively. In HT the increased SNA is associated with decreased parasympathetic activity 
(1).  
   There is a positive feedback mechanism between the SNS and the RAAS. The SNS 
increases RAAS activity and, in turn, angiotensin II stimulates the adrenergic centers so that a 
vicious circle develops. 
 
 
1.3.2. Baroreflex sensitivity 
 
The baroreflex is one of the most important mechanisms for preventing excessive changes in 
BP.  
   The changes of BP wave amplitudes lead to prompt modulation of HR via the baroreflex 
mechanism. The BRS is an index of the sensitivity of arterial baroreflex modulation of HR 
but it has a wide range of variability in a healthy population. In healthy individuals the BRS 
decreases after standing up compared to a lying position because of an increased sympathetic 
tone suppresses the vagal cardiac efferent tone (14). In primary HT there is an increased SNA, 
the set point of the baroreflex is displaced upwards and the BRS is decreased. The arterial 
BRS is a marker for parasympathetic activity which is responsible for short-term CV 
regulation. The BRS may be useful as a risk marker for CV diseases (15). Decreased vagal 
BRS is suggested to be an independent predictor of poor survival following an acute 
myocardial infarction even 28 days later, according to the results of the ATRAMI study (16). 
In heart failure, decreased BRS is associated with the severity of the disease and it is an 
independent predictor of long-term survival (17). BRS decreases with the higher grade of HT 
and is related to several CV risk factors (15). Impaired BRS is also associated with diastolic 
dysfunction in HT patients (18) and the BRS is also suggested to be a sensitive early marker 
in diabetic neuropathy (19). Decreased spontaneous BRS were observed in HT (20), and with 
elevated pulse wave velocity (21, 22). 
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1.3.3. Evidence for increased sympathetic activity in patients with hypertension 
 
Tachycardia is a simple but significant indicator of SNA and it is often related to hyperkinetic 
circulation in borderline HT. Furthermore tachycardia is an important marker of CV risk (23, 
24). Tachycardia is associated with significantly higher BP (25).  
   In the Goldstein meta-analysis of 32 studies, NE levels were higher in HT patients (26). 
Compared to normotensive individuals the total NE spillover was only approximately 20-25% 
higher in HT patients, but the regional NE spillover was about 150% higher in HT patients 
(27). 
   Using microneurography the muscle SNA was higher in patients with HT compared to 
normotensives (28, 29) but skin SNA was not elevated, indicating that increased SNA is not a 
general, whole body phenomenon (30).  
   In the early stage of HT the SNA mainly increases cardiac output, while in the late stage it 
increases the peripheral resistance (31). 
 
 
1.4. Hypertension and diabetes mellitus 
 
HT is common feature of both type 1 and typically type 2 DM. Office BP readings are in the 
normal range for a long time in DM, and usually it is the nocturnal BP which increases first. 
Therefore monitoring 24-h ambulatory BP in apparently normotensive patients with DM is a 
useful prescribed diagnostic procedure (8).  
   HT is more common in individuals with type 2 DM compared to the general population; the 
prevalence is about 60-70% of the type 2 diabetic population (32). In HT patients, type 2 DM 
develops 2.5 times more frequently (33). In type 1 DM, HT appears after the development of 
diabetic nephropathy (34). The development of HT accelerates the course of micro- and 
macrovascular complications in diabetic patients. In the MRFIT Study coronary artery disease 
mortality was 2-3-times higher among HT diabetic patients (35). 
   The CV morbidity and mortality in DM is 2.5-7.2 times higher compared to the general 
population (33).  
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   In 1999 the AHA, examining the CV complications of DM, made the statement that, from 
the point of view of CV medicine, it may be said: “diabetes mellitus is a CV disease.” (36). 
 
 
1.4.1. Diabetic polyneuropathy 
 
The diabetic polyneuropathy has 3 types as classified by Dyck et al. (37). The most common 
and, in terms of the prognosis, the most important complications of DM are the autonomic 
and sensorimotor neuropathies, which have been subjected to intensive research over the past 
decades (38). 
 
 
1.4.1.1. Cardiac autonomic neuropathy 
 
The CAN may cause symptoms ranging from resting tachycardia to sudden cardiac death. A 
disturbance of the sympatho-vagal balance leads to deficient reductions in HR and BP during 
the night, resulting in the "non-dipper" phenomenon. The early parasympathetic damage may 
lead to a relative sympathetic overactivity with the development of an increased HR before 
HT has appeared (39). 
 
 
1.4.1.2. Peripheral sensory neuropathy 
 
The PSN, which can be characterized quantitatively, is considered as the most important 
pathogenetic factor for the development of the diabetic foot syndrome, a condition mostly 
responsible for lower-extremity amputations. The EURODIAB IDDM Complication Study, 
involving 3250 insulin-dependent diabetic patients, identified well-known and new risk 
factors for the development of PSN. Significant correlations were demonstrated between the 
PSN with age, duration of diabetes, diabetic retinopathy and high-density lipoprotein 
cholesterol, presence of CV disease, elevated DBP, triglyceride, cigarette smoking, height, 
ketoacidosis, retinopathy, microalbuminuria, and metabolic control (40). There are likewise 
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associations between HT and PSN in type-1 and type-2 DM and in elderly nondiabetics (41, 
42). The role of HT in the development of PSN is not well understood, although a positive 
correlation in nondiabetics also has been described (42). On the contrary, there are results 
showing that HT might be protective against the development of PSN, mainly in the elderly 
patients, with or without DM (43, 44). 
 
 
1.5. The resistant hypertension 
 
HT is poorly controlled not just in Hungary, but also in Europe and worldwide. In Hungary in 
2007 the BP of 46% of the nondiabetic HT population and only 8.5% of the diabetic HT 
population was in the goal range (45). 
   In 2013, according to the ESH and the ESC, HT is defined as therapeutically resistant when 
an appropriate lifestyle modification with a triple antihypertensive drug combination (a 
diuretic and two other antihypertensive drugs belonging to different classes but not 
necessarily including a mineralocorticoid receptor antagonist) at adequate doses fail to lower 
SBP and DBP values to <140 and 90 mmHg (8). But there are some other frequently used 
definitions of RHT (Table 1) (46).  
   The real prevalence of RHT is not known, it varies over a wide range depending on the 
definition and goal BP values used at different data collection locations, the population 
examined and the level of medical screening (etc. work place, general practitioner office, 
hospital, clinic, HT center, and so on). The prevalence in general practitioner offices is 
suggested to be less than 5% of the overall HT population, while in clinical trials 10-20% and 
in HT centers (47).  
   According to an ESH Newsletter, published in 2011, the prevalence of RHT is 2.9-43% 
(48). 
   The prevalence of TODs such as left ventricular hypertrophy, retinopathy, 
microalbuminuria and thicker arterial intima-media layer are higher in true RHT by a 50-
100% range compared to well-controlled hypertensives. The risk of CV diseases is also 2.5-5 
times higher (49, 50).  
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Table 1 The frequently used definitions of resistant hypertension. 
2003 ESH-ESC guidelines (51) 
Hypertension may be termed resistant to treatment, or refractory, when a therapeutic plan that 
has included attention to lifestyle measures and the prescription of at least three drugs in 
adequate doses has failed to lower systolic and diastolic blood pressure sufficiently. 
2007 ESH-ESC guidelines (52) 
Hypertension is usually defined resistant or refractory to treatment when a therapeutic plan 
that has included attention to lifestyle measures and the prescription of at least three drugs 
(including a diuretic) in adequate doses has failed to lower systolic and diastolic blood 
pressure to goal. 
JNC 7 (2003) (4) 
Resistant hypertension is defined as the failure to achieve goal BP in patients who are 
adhering to full doses of an appropriate 3-drug regimen that includes a diuretic. 
AHA 2008 (53) 
Resistant hypertension is defined as blood pressure that remains above goal in spite of the 
concurrent use of 3 antihypertensive agents of different classes. Ideally, one of the 3 agents 
should be a diuretic and all agents should be prescribed at optimal dose amounts. 
 
   The increased SNA has a key role in generating and sustaining primary, true RHT. The 
TODs of HT may also come with increased SNA leading to further progressions. The possible 
causes of RHT are summarized in Table 2.  
   In RHT, the prevalence of so called identifiable causes is fourfold higher than in non-RHT 
(54). Pseudoresistant and secondary RHT forms are usually tractable, and they can convert to 
be controlled or well-controlled HT.  
 
 
1.5.1. Pseudoresistant hypertension 
 
One of the most important and most common causes of RHT in primary care concerns 
problems with BP measurement. The technical issues involved here are the improper cuff 
(e.g., usually smaller-than-required in obese patients, inaccurate manometer), the lack of a 
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few-minutes (e.g., usually 5 minutes) rest prior to measurement, and  markedly atherosclerotic 
arteries causing so called pseudohypertension (10-15 mmHg higher pressure is needed to 
compress the cuff compared to intra-arterial pressure). A positive Osler manoeuvre and the 
presence of calcified brachial arteries by radiography can support the pseudohypertension 
(55). 
 
Table 2 Possible causes of resistant hypertension (56). 
1. Pseudoresistant hypertension 
 Improper blood pressure measurement technique 
 Improper cuff 
Missing rest prior to measurement 
Difficulty to compress atherosclerotic arteries 
"White-coat effect" 
Poor patient adherence and/or compliance 
2. Secondary resistant hypertension 
 Co-morbidities and conditions 
 Obesity 
Excess alcohol consumption 
Chronic pain 
Obstructive sleep apnoea syndrome 
Depression 
Drugs, health products, poisoning 
 Non-steroid anti-inflammatory drugs 
Excess glucocorticoid activity 
Sympathomimetics 
Oral contraceptives 
Sibutramine 
Cocaine, amphetamine, „crack” „speed” 
Erythropoietin 
Cyclosporine 
Tricyclic antidepressant drug 
Lead, mercury 
Secondary hypertension 
 Primary aldosteronism 
Chronic kidney disease 
Renal artery stenosis 
Pheochromocytoma 
Cushing's syndrome 
Hyperparathyroidism 
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   The "white-coat effect" means that office BR readings are high while home BP reading are 
within goal values. This white-coat effect can be suspected if HT-related TODs are less severe 
than could be expected from the office BP. The prevalence of the white-coat effect is 
approximately 20-30% (54). The white-coat effect is very probable if the office BP is 140/90 
mmHg and the mean BP of 24 home measurements per 7 days is less than 125/75 mmHg. The 
patients showing the “white-coat effect” have a lower CV risk and TOD compared to true 
RHT patients (57). 
   Non- or poor adherence to prescribed drugs and/or non-compliance make it more difficult to 
reach the goal BP of HT patients. The non-compliance prevalence is higher (50%) in primary 
care than in centers specialized on HT (16%) (53, 58). Non- or poor adherence usually can be 
due to intolerance (objective and/or subjective ones) (54). Its diagnosis is quite difficult, 
because the sensitivity of methods such as a personal interview with the patient, the so called 
„clinical experience” or the counting of tablets is about 50% effective, although their 
specificity is over 85% (58, 59). Non-adherence may be related to the level of patient 
education and/or accomplishment, complexity of the regimen, anticipated or actual side 
effects, or interestingly the idea that „drugs are poisons”.  
 
 
1.5.2. Secondary causes of resistant hypertension 
 
After excluding all the pseudoresistant causes and revealing co-morbidities, drugs and health 
products in a case of suspected RHT the final step is to look for possible secondary causes.  
   PA is a common form of endocrine HTs and is the most important in RHT. The 
inappropriate production of aldosterone results in sodium retention and suppression of renin. 
It is usually caused by an adrenal adenoma on one side or bilateral hyperplasia of the 
adrenocortical zone glomerulosa.  
   Classically PA is featured with hypokalemia, but according to newer data of the ESH 
hypokalemia is only presented in 9-37% of the all PA cases (60). The prevalence of PA is 15-
20% in RHT and less than 1% in the general HT population. By applying the plasma 
aldosterone level/plasma renin activity ratio as a screening test in HT patients, regardless of 
the presence or absence of hypokalemia, a much higher prevalence of PA was found, 12% 
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(60). But 77% prevalence in secondary HT has also recently been published (61). In an 
endocrine guideline screening for PA the RHT patients is recommended (62).  
   In RHT pheochromocytoma as a secondary cause should be suspected if high BP appears in 
attacks with palpitation, headache, becoming pale, sweating, angina, arrhythmia, pulmonary 
edema, loss of weight. The typical triad is paroxysmal headache, palpitation and sweating. 
The incidence of pheochromocytoma is very low, 2-8 patients per 1 million people (63) and in 
the HT population the prevalence is about 0.2% (61). Catecholamine-secreting tumors arise 
from chromaffin cells, and the term „pheochromocytoma” in clinical practice covers both the 
adrenal (true) pheochromocytomas and the extra-adrenal sympathetic paragangliomas. These 
tumors have similar symptoms (63). The most sensitive and specific method for screening for 
pheochromocytomas is the measurement of metanephrine and normetanephrine levels from a 
24-hour urine sample or from a plasma sample. The older method of determining vanillyl 
mandelic acid in a 24-hour urine sample is not specific. If a screening is positive, then an 
imaging technique is required to localize the tumor. If two of the typical triad are presented 
then screening for pheochromocytoma is markedly advised.  
 
 
1.5.3. Resistant hypertension and the kidney 
 
The kidney is also involved in the autonomic regulation of BP. On the one hand it partially 
generates, and on the other hand it receives impulses that force the development of, and 
sustain, sympathetic overactivity. Animal studies have indicated that the kidney contains 
different afferent nerves which may cause reflex SNA and so give rise to systemic BP (64, 
65).  
   Renal nerves arise from T10-L2 spinal segments, arborize around the renal artery and 
primarily lie within the adventitia. All the major renal structural elements are innervated, 
including vascular smooth muscle cells (including pre- and postglomerular arterioles), 
tubules, mesangium and renin-secreting cells (66). The juxtaglomerular apparatus, including 
the renin-containing granular cells is also innervated (67).  
  Kidney function is independent from tonic renal SNA, after a renal denervation there no 
changes in RBF and GFR have been found (68). It has also been confirmed after kidney 
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transplantations that the renal vascular and tubular function is independent from neural 
control (69). 
   The RBF autoregulation has two components: a slower tubuloglomerular feedback and a 
faster myogenic one (70). In normal conditions there is a tonic renal SNA that increases renal 
tubular sodium reabsorption and renin secretion, but it does not have a vascular effect (70).  
   Low-intensity (frequencies ≤ 1.0 Hz) stimuli of renal nerves result first in an increase of 
renin secretion and then in tubular sodium reabsorption with no change in the GFR and/or 
RBF. High-intensity (frequencies ≥ 1.0 Hz) stimuli will cause decreased RBF and GFR in 
addition to increased renin secretion and sodium reabsorption (70, 71).  
   Physiologically the stimulation of afferent sensory renal nerves inhibits the sympathetic 
efferent renal nerves, resulting in natriuresis (renorenal reflex). However, in HT animal 
models this negative feedback is impaired and stimuli from afferent sensory nerves cannot 
decrease or further increase the renal SNA (72, 73).  
 
 
1.5.4. Neurovascular pulsatile compression of the brain stem 
 
Trigeminal, glossopharyngeal neuralgias and hemifacial spasm are caused by arterial 
compression, referred to as NVPC, by elongated and/or not typically placed arteries. About 
forty years ago it was reported for first time by Jannetta and his colleagues that NVPC of the 
RVLM also can be behind arterial HT. The PICA and/or the VA can compress the root-entry 
zone of cranial nerves IX and X and/or the C1 neurons containing the retro-olivary sulcus 
near to the root-entry zone on the left side (Figure 4) (74, 75, 76, 77, 78).  
 
Figure 4 Types of neurovascular pulsatile compression. 
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   An MRA can evaluate the diagnosis of NVPC (Figure 5). Without angiography just an MRI 
is not so sensitive for evaluating any compression. 
 
Figure 5 MRA images of neurovascular pulsatile compression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.5. Non-pharmacological, non-lifestyle based therapy for hypertension 
 
There are many novel technologies for non-pharmacological, non-lifestyle based therapy for 
HT. They have in common the attempt to reduce the sympathetic overactivity instrumentally. 
They are summarized in Table 3.  
   Non-selective surgical sympathectomy effectively already decreased the BP in ’30s and 
’50s of the last century. However this technique unfortunately had severe side effects, causing 
significant worsening of the quality of life (79, 80, 81). 
 
VA 
PICA 
PICA 
PICA 
VA 
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Table 3 Different non-pharmacological, non-lifestyle based therapies for hypertension. 
 Renal denervation 
 Baroreceptor activation therapy 
 Iliac arteriovenous fistula 
 Carotid body ablation 
 Deep brain stimulation 
 Decompression of the rostral ventrolateral medulla 
 Device-guided respiration 
 CPAP (in OSA) 
 Stent repair of aortic coarctation 
 Endovascular repair of renovascular disorders 
 Surgical therapy for endocrine HT (adrenalectomy, paraganglionectomy) 
 
The development of endovascular catheter technology in our day permits selective RDN in 
the adventitia of the renal arteries. The radiofrequency energy is a heat energy that is 
delivered directly to the nerves in the adventitia and destroys them while preserving other 
structures of the arterial wall. It may be that renal nerves much more sensitive to heat energy 
and vibration than other tissues close to them (82). This is a relatively new technology but it 
also has many different forms (Table 4). 
 
Table 4 Technologies to achieve selective renal sympathectomy. 
 Radiofrequency ablation 
o generation 1: unifocal 
o generation 2: multifocal 
 Ultrasound therapies 
o endoluminal: high intensity non-focused 
o external: low intensity focused 
 Microinjection of neurotoxin 
 Cryotherapy 
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   In case of NVPK of the RVLM on the left side, an NVD can significantly decrease both the 
SBP and the DBP and can improve the sensitivity to drug treatment (83, 84, 85). 
 
 
2. AIMS 
 
1. To investigate PSN in HT patients without DM and also to evaluate PSN, CAN and 
BRS in HT patients associated with DM. Additionally, to look for associations 
between the duration of HT, the duration of DM, the BP values and the severity of any 
CAN and PSN. 
 
2. To retrospectively collect and analyze the BP levels and the therapy of patients with or 
without NVD of NVPC over a 2–year period. 
 
3. To retrospectively investigate whether there is an association between the types of 
NVPC and the SBP and DBP before and after NVD and/or between the types and the 
changes of BP after NVD. 
 
4. In one case there was an opportunity to monitor the changes of sympathetic and 
parasympathetic activity before and after an NVD. 
 
5. To observe the changes of BPs and SNA before and after RDN of 4 RHT patients.  
 
 
3. PATIENTS AND METHODS 
3.1. Cardiac autonomic neuropathy 
 
In the first part of this investigation 18 NDHT, 10 DHT, and 11 C individuals were enrolled. 
An oral glucose tolerance test was performed in all nondiabetic individuals in order to exclude 
DM and impaired glucose tolerance. Impaired fasting glucose levels were excluded from 
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fasting plasma glucose measurements. In the second part of this investigation 22 NDHT, 18 
DHT and 15 C individuals were enrolled. 
   Subjects with arrhythmias, bundle-branch block, congestive heart failure, valvular disease, 
acute myocardial infarction, coronary heart disease, cardiomyopathy, electrolyte disturbances, 
renal failure, or any other condition causing autonomic and/or sensory neuropathy in the 
history were excluded from the study. For at least 12 hours before the examination, the 
patients did not drink coffee or alcohol, did not smoke, and did not perform any strenuous 
physical activity.  
   The CAN was assessed by means of the five standard CRTs proposed by Ewing et al. (86). 
The parasympathetic function was characterized via the changes in HR in response to deep 
breathing, to the Valsalva manoeuvre, and to standing up (30/15 ratio). The sympathetic 
function was characterized via the SBP changes in response to standing up and via the DBP 
changes in response to a sustained handgrip. In all tests, normal values were scored 0, 
borderline values 1, and abnormal values 2. The sum of the scores gave the total CAN score. 
A patient was considered as CAN-positive if the score was 2 or higher (at least 2 tests with 
borderline or 1 test with abnormal values). A score of 0–1 was taken as normal, 2–3 as mild, 
4–6 as moderate, and 7–10 as severe CAN. 
 
 
3.2. Baroreflex sensitivity 
 
   Spontaneous BRS was calculated in 10 minutes lying and 10 minutes standing positions via 
a sequence (time-domain) method using a software package for BRS analysis (Nevrokard 
BRS 5.1.3; Medistar) (Figure 6).  
   BRS calculation by sequence method is based on the quantification of sequences of at least 
three beats in which SBP consecutively increases or decreases, which is accompanied by 
changes in the same direction of the RRI of the subsequent beats. The software scans the RRI 
and SBP records, identifies sequences and calculates the linear correlation between RRI and 
SBP for each sequence. 
 
 
25 
 
Figure 6 The time-domain baroreflex sensitivity by Nevrokard software. 
 
The SBP and RRI files were generated via the beat-to-beat data acquisition system by finger 
photoplethysmography (Finometer, TPD Biomedical Instruments, Finapres Medical Systems 
B.V., Amsterdam, The Netherlands) at 200 Hz combined with an ECG (Figure 7 and 8).  
 
Figure 7 Measurement with Finometer. 
 
   The photoplethysmography technique was developed by Peñáz in 1973 (87). Based on it the 
continuous beat-to-beat measurement of the arterial BP in a finger and producing a real-time 
display of the arterial pressure waveform with Finapres was introduced in the early 1980s. 
The Finometer is a newer generation based on this prelude; it is a non-invasive built-in-one 
computerized device to measure the brachial arterial pressure using a pneumatic inflatable 
finger cuff. The brachial arterial BP wave is reconstructed in waveform and level. For this 
purpose an upper arm cuff return-to-flow systolic pressure determination is used and analysed 
by an appropriate algorithm. This reconstruction procedure runs fully automatically, which is 
a default setting of the Finometer (88).  
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   In the wall of the inflatable finger cuff is a photo-electric, infrared plethysmograph, which 
measures the real time blood volume of the finger (Figure 8). The changes of the blood 
volume in the finger are modulated by the changes of the systemic arterial BP associated to 
cardiac cycles. The elasticity of the vessel wall means resistance inverse to blood volume 
therefore transmural pressure of the arterial wall should be settled up. A fast pneumatic servo 
system and a dynamic servo set point adjuster assure arterial unloading at zero transmural 
pressure and consequent full transmission of arterial BP to cuff air pressure (89). The pressure 
inside the cuff represents the intra-arterial finger pressure with a minimal delay (90).  
 
Figure 8 The pneumatic inflatable finger cuff. 
 
 
 
 
 
 
 
3.3 Peripheral sensory neuropathy 
 
The peripheral sensory function was characterized via the CPTs as measured with a 
Neurometer (Neurotron Inc., Baltimore, MD, USA) (Figure 9). Median and peroneal nerves 
(digital branches) were assessed. The intensity of the current issued by the device ranged 
between 0.01 and 9.99 mA. For both the median and the peroneal nerves, the CPTs were 
measured at 2000, 250, and 5 Hz in order to assess large and small myelinated, as well as 
small unmyelinated, sensory nerve fiber function, respectively (91, 92, 93). 
 
Figure 9 The Neurometer device. 
 
 
 
 
 
Photo cell LED 
inflatable 
balloon 
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   The data obtained on the control patients and the patients treated for HT were compared 
statistically by parametric ANOVA or nonparametric ANOVA (Kruskal–Wallis). Pairwise 
comparisons were made using the Student-Newman-Keuls test. The relationships between the 
results of the examinations and the various patient data were analyzed using Pearson’s 
correlation and multiple linear regression tests. A probability value of <0.05 was considered 
as significant. Means ± SD are reported. 
 
 
3.4. Neurovascular pulsatile compression 
 
Between 2000 and 2004, using a neurosurgical database, an MRA was performed in 50 
resistant primary HT cases. The criterion for MRA was the prior exclusion of all the possible 
secondary causes of RHT.  
   For the MRA a 1T Sigma Horizont LX General Electric device with a 3D spoiled gradient 
echo /3D time-of-flight technique was used. The volume thickness was 60-70 mm and the 
slice thickness was 1 mm. The time of echo was 2.9 msec, the time of repetition was 33 msec 
and the flip angle was 20 degrees. The maximum intensity projection was reconstructed in an 
optional plane. The requirement for a positive MRA finding was a touch between the looping 
arteries and the surface of the RVLM at the root entry-exit zone of nerves IX and X, or 
between the looping arteries and the cranial nerves IX and X on the left side. All the MRA 
readings were done by the same expert radiologist. 
   Based on possible anatomical variations according to MRA, different groups were formed. 
In group BS the NVPC affected only the brain stem (on right side: BSR, on left side: BSL, on 
both sides: BSB). In group N the NVPC affected only the nerves IX-X (on right side: NR, on 
left side: NL, on both sides: NB). In group D dual NVPC could be observed affecting both the 
brain stem and the nerves (on right side: DR, on left side: DL, on both sides: DB).  
   NVDs were performed under anaesthesia. Following a retromastoidal suboccipital 
craniotomy on the left side, identifying the anatomical structures a tissue-friendly haemostatic 
sponge (Spongostan
TM
) was placed between the arteries and the nerves or the surface of the 
RVLM. All the procedures were performed in the Department of Neurosurgery in Szeged by 
the same neurosurgeon. 
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   BP readings were recorded at the time of the last visit, a few days before the NVD, and at 
the end of 1st postoperative week in the 1st Department of Internal Medicine in Szeged which 
is one of the Excellence Centers of the ESH. BP readings were performed by manual 
sphygmomanometer. Means of two measurements were calculated. 
   To follow-up the changes of BP values the data of control examinations performed 1, 3, 6, 
12 and 24 months after the intervention or after MRA in the non-operated cases were 
analyzed. During the control consultations, physical examination, BP measurement and 
checks on the therapy were carried out. 
   Data were compared statistically by means of parametric ANOVA. The relationships 
between the types of the compressions and the BP levels were analyzed with Pearson’s 
correlation test. Probability levels p<0.05 were taken as significant. Means ± SD are reported. 
   The CAN, the BRS and the plasma NE were estimated in a case of a 57-year-old white 
woman with HT resistant to 10 different antihypertensive agents (Table 23). The duration of 
her HT was 36 years. She had impaired glucose tolerance, her BMI was 26.33 kg/m
2
 and her 
GFR was 79.5 ml/min. She had TOD of mild left ventricular hypertrophy (the posterior wall 
was 10 mm, and the interventricular septum was 11 mm) and Keith–Wagener–Baker grade II 
hypertensive retinopathy. There were no trigeminal neuralgia or hemifacial spasms in her case 
history. After excluding all of the possible secondary causes, an MRA was performed as 
detailed above. 
   The spontaneous BRS, via a sequence method, were calculated from ECG and BP data 
recorded by a Finometer device on the day of NVD, just prior to the procedure, and on 
postoperative day 9. The technique is detailed above.  
   The NE was quantitatively determined in plasma by a competitive enzyme immunoassay in 
a microtiter plate format (2-CAT RIA, DIAsource Immuno-Assays S.A., Louvain-La-Neuve, 
Belgium). Samples for NE were collected on the day of NVD just prior to the procedure and 
on postoperative days 1 and 9. 
   Before and after NVD of this woman, a 24-hour ABPM was performed with an ABPM-04 
device (Meditech Ltd., Budapest, Hungary). 
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3.5. Transcatheter renal denervation 
 
Four validated RHT patients agreed to RDN. Their parameters are summarized in Table 5. 
Before RDN and after it, on the post-procedure day 1, a 24-hour ABPM was performed in 
every case (ABPM-04 device, Meditech Ltd., Budapest, Hungary). Mean SBP and DBP 
values were analyzed in this work. The spontaneous BRS via a sequence method were 
calculated from ECG and BP data recorded with a Finometer device on the day before RDN 
and on post-procedure day 1. The technique is detailed above. 
 
Table 5 Clinical parameters of patients undergoing renal denervation. 
Patients 
52 year old 
woman 
50 year old 
woman 
39 year old 
woman 
62 year old 
man 
BMI (kg/m
2
) 39.1 29.5 32.8 39.9 
co-morbidities, 
TOD 
obesity, 
hyperlipidemia 
LVH, HF (NYHA 
I) 
hypertensive 
angiopathy st. II 
hyperlipidemia, 
LVH, mitral insuff. 
I-II, aortic insuff. I , 
hypertensive 
angiopathy st. II 
obesity, 
hyperlipidemia, 
T2DM 
LVH, PSVT (RF 
ablation), HF 
(NYHA I), 
NVD (24 March 
2010) 
obesity, 
hyperlipidemia, IGT 
LVH, atrial 
fibrillation, HF 
(NYHA I), OSAS 
hypertensive 
angiopathy st. II, 
NVD (10 Feb 2010) 
antihypertensive 
medications 
prior to RDN 
valsartan 2x160 mg 
amlodipine 2x10 
mg 
nebivolol 2x5 mg 
doxazosin 2x6 mg 
indapamide 2x1 tbl. 
clopamide 20 mg 
urapidil 3x90 mg 
spironolactone 50 
mg 
dihydralazine 
3x12.5 mg 
minoxidil 1x5 mg 
valsartan 2x80 mg 
hydrochlorothiazide 
2x12.5 + 25 mg 
perindopril 2x10 
mg 
amlodipine 1x10 
mg 
indapamide 1x2.5 
mg 
urapidil 3x90 mg 
prazosin 3x6 mg 
doxazosin 2x4 mg 
carvedilol 1x6.25 
mg 
dihydralazine 2x25 
mg 
amilorid 1x50 mg 
valsartan 2x160 mg 
doxazosin 2x4 mg 
urapidil 3x90 mg 
carvedilol 2x25 mg 
amlodipine 2x5 mg 
spironolactone 
2x25 mg 
indapamide 2x1.5 
mg 
dihydralazine 3x50 
mg 
rilmenidine 2x1 mg 
guanfacine 2x1 mg 
perindopril 2x5 mg 
amlodipine 2x10 
mg 
indapamide 2x1.5 
mg 
urapidil 3x90 mg 
doxazosin 2x6 mg 
metoprolol 3x25 mg 
dihydralazine 3x25 
mg 
spironolactone 1x50 
mg 
guanfacine 2x1 mg 
 
   RDNs were performed by the joint guidance of the Symplicity
TM
 Catheter System 
producing Medtronic Inc. and Krum et al. who first described it in 2009 (93). An invasive 
cardiologist performed the RDNs, but the first time an interventional radiologist also 
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cooperated in the process. The alprazolam pre-medication and the intraoperative analgesia 
with propofol-fentanyl combination were provided by an anaesthesiologist. 
   All the RDN procedures were performed in the Division of Invasive Cardiology, Second 
Department of Medicine and Cardiology Center, University of Szeged using an Innova 
2000™ (GE Healthcare) x-ray machine with angiography. The RDN procedure using a 
Symplicity
TM
 Catheter System was performed via a femoral approach (6F femoral guide) after 
an intra-arterial nitro-glycerine administration in analgosedation. The catheter was connected 
to a radiofrequency generator. The anatomical eligibilities - defined as ≥4 mm diameter, ≥20 
mm length, not more than one main renal artery, no significant renal artery stenosis, and/or 
previous renal artery intervention – were confirmed via renal CT angiography in all cases. 
Participants were given heparin – average 5000 IU – intravenously to achieve an activated 
clotting time of more than 250 s. Hydration and acetyl salicylic acid also were applied for all 
participants. After the confirmation of a proper wall-contact from distal to proximal five-to-
six discrete, low-power radiofrequency treatments were applied separated rotationally and 
longitudinally along the length of renal arteries separately. Each low-power radiofrequency 
treatment lasted ≤2 minutes with only a 6 Watt energy. During the procedure the system 
calculates the radiofrequency energy delivered to the nerves by the impedance and the heat 
was detected via an electrode at the catheter tip. There were no acute vascular complications 
after the RDN procedure (94).  
 
   All the investigations were approved by the local Human Investigation Review Board, 
University of Szeged (31/2006, 2/2007, 109/2011), and all patients provided written informed 
consent. 
 
 
4. RESULTS 
4.1. Neuropathies in hypertension and diabetes mellitus 
 
All the HT patients were treated with multiple combinations of antihypertensive drugs, but the 
two HT groups did not differ significantly in the number of combinations (NDHT 4.44 ± 0.37, 
DHT 4.2 ± 0.33). Table 6 and Table 7 summarize the types and frequencies of 
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antihypertensive medications used by the patients in the first and second part of 
investigations. 
 
Table 6 Frequency of use of antihypertensive drugs in the two patient groups in the first part 
of investigation. 
 NDHT (n=18) DHT (n=10) p 
Angiotensin-converting enzyme inhibitor 15/18 6/10 NS 
Angiotensin receptor blocker 1/18 3/10 NS 
Beta-blocker 6/18 5/10 NS 
Dihydropyridine calcium channel blocker 17/18 10/10 NS 
Non-dihydropyridine calcium channel blocker 1/18 1/10 NS 
Imidazoline I-1 receptor agonist 5/18 6/10 NS 
Alfa-1-blocker 2/18 1/10 NS 
Alfa-1-blocker + beta-blocker in fixed combination 6/18 1/10 NS 
Alfa-1-blocker-alfa-2-agonist 5/18 1/10 NS 
Thiazide diuretics  14/18 7/10 NS 
 
 
Table 7 Frequency of use of antihypertensive drugs in the two patient groups in the second 
part of investigation. 
 NDHT (n=22) DHT (n=18) p 
Angiotensin-converting enzyme inhibitor 17/22 14/18 NS 
Angiotensin receptor blocker 5/22 3/18 NS 
Beta-blocker 8/22 5/18 NS 
Dihydropyridine calcium channel blocker 20/22 17/18 NS 
Non-dihydropyridine calcium channel blocker 1/22 1/18 NS 
Imidazoline I-1 receptor agonist 4/22 6/18 NS 
Alfa-1-blocker 4/22 2/18 NS 
Alfa-1-blocker + beta-blocker in fixed combination 8/22 4/18 NS 
Alfa-1-blocker-alfa-2-agonist 5/22 2/18 NS 
Thiazide diuretics  18/22 15/18 NS 
 
   In the first part of the investigation, of the DHT patients 1 was on premix insulin and 1 
received only dietary treatment at the time of the investigations, the others were on oral 
antidiabetics. In the second round, 1 patient was on oral antidiabetics + insulin therapy, 6 
patients received only dietary treatment, and the others were on oral antidiabetics. 
   In the first part of the investigation the two HT groups did not differ significantly in BMI or 
treated SBP or DBP, but these parameters were significantly higher in both of them than in 
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group C (Table 8). The clinical parameters for enrolled individuals in the second part are 
summarized in Table 10. 
 
Table 8 Clinical parameters of investigated groups in the first part of investigation. (*p < 0.05 
NDHT vs. C and DHT vs. C; †p < 0.05 DHT vs. C and NDHT) 
 C (n=11) NDHT (n=18) DHT (n=10) 
Gender 5 M, 6 F 8 M, 10 F 4 M, 6 F 
Age (yr) 44.9±7.3 54.4±13.9 51.0±8.6 
Duration of HT (yr) - 10.6±9.8 12.3±9.9 
Duration of DM (yr) - - 6.1±7.7 
BMI (kg/m
2
) 23.7±4.0 28.2±4.7
* 28.5±2.8* 
SBP (mmHg) 116.8±11.7 134.9±18.0
* 131.6±12.5* 
DBP (mmHg) 64.1±6.2 84.2±11.8
* 85.6±8.3* 
Blood glucose (mMol/L) 4.8±0.6
† 5.16±0.7† 8.2±3.1 
HbA1c (%) 5.3±0.4
† 5.7±0.3† 6.8±1.3 
 
 
Table 9 Clinical parameters of investigated groups in the second part of investigation. (*p < 
0.05 DHT vs. C) 
 C (n=15) NDHT (n=22) DHT (n=18) 
Gender 5 M, 10 F 5 M, 17 F 6 M, 12 F 
Age (yr) 50.2±5.9 57.2±5.5 57.8±4.7 
Duration of HT (yr) - 8.7±5.2 15.0±11.7 
Duration of DM (yr) - 8.4±7.9 - 
BMI (kg/m
2
) 26.4±3.7 29.1±3.1 30.9±4.6 
SBP (mm Hg) 123±6.0 129±13.8 137±19.1
* 
DBP (mm Hg) 71±8.0 75±9.2 72±10.0
* 
Blood  glucose (mMol/L) 4.6±1.4 5.1±1.1 6.7±3.7 
HbA1c (%) 4.5±1.1 4.7±1.2 6.2±2.7 
 
   Table 11 lists the means of the CRTs. In group DHT, one patient did not have CAN with a 
normal value in the reflex tests and in group NDHT, two patients did not have CAN, but both 
had borderline value in the reflex tests. The CAN score did not differ significantly between 
the HT groups (NDHT 4.6 ± 2.5; DHT 3.9 ± 1.96). Group C was free of autonomic 
neuropathy. There were no patients with sympathetic neuropathy alone either in the DHT or 
in the NDHT group. Two patients had parasympathetic neuropathy alone both in the DHT 
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(2/10) and in the NDHT (2/18) groups. In group DHT, 7 patients and, in group NDHT, 14 
patients had sympathetic plus parasympathetic neuropathies together. 
 
Table 11 Results of cardiovascular reflex tests in the first part of investigation. (*p < 0.05 
NDHT vs. C and DHT vs. C) 
 C (n=11) NDHT (n=18) DHT (n=10) 
Deep breathing (beat/min) 24.8±7.1 13.2±7.6
* 16.7±8.9* 
Valsalva manoeuvre 1.7±0.3 1.4±0.2
* 1.4±0.4* 
30/15 ratio 1.2±0.1 1.0±0.1
* 1.0±0.1* 
Standing up (mmHg) 7.7±8.8 19.8±8.8
* 13.5±6.6 
Sustained handgrip (mmHg) 26.4±8.7 20.4±11.2 18.8±12.8 
 
   The CRT results are presented in Table 12. In group NDHT, 2 patients did not have CAN, 6 
patients had mild, 6 patients had moderate, and 4 patients had severe CAN. In group DHT, 1 
patient did not have CAN, 2 patients had mild CAN, 7 patients had moderate CAN, and none 
had severe CAN. In group C, no CAN has been observed at all. 
 
Table 12 Distribution of cardiovascular reflex tests in hypertensive groups in the first part of 
investigation. 
 Number of patients  
Abnormal (2 points) Borderline (1 point) Normal (0 point) 
DHT NDHT DHT NDHT DHT NDHT 
Deep breathing 3 8 2 3 5 7 
Valsalva manoeuvre 0 3 4 1 6 14 
30/15 ratio 6 12 0 2 2 4 
Standing up 0 2 7 13 3 3 
Sustained handgrip 4 6 1 1 5 11 
 
   Data on sensory nerve function are shown in Table 13. The CPTs on the peroneal nerve at 
250 Hz in group NDHT and at 250 and 5 Hz in group DHT were higher compared with group 
C, but the differences were not significant. All the CPTs of the CAN-free patients were within 
the normal range. 
   In group NDHT, we found a positive correlation between the severity of CAN and the 
known duration of HT (r = 0.64, p = 0.008). In group DHT, there was no correlation between 
the duration of HT and the severity of CAN. In group DHT, there was a positive correlation 
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between the duration of HT and the CPTs measured on the lower extremities at 250 Hz (r = 
0.68, p = 0.04) and 5Hz (r = 0.68, p = 0.04). The duration of DM also showed a positive 
correlation with the CPTs measured on the lower extremities at 250 Hz (r = 0.8, p = 0.01) and 
5 Hz (r = 0.74, p = 0.02). Such a correlation was not found in group NDHT. When multiple 
linear regression test was used, in group NDHT there was a correlation between the age and 
the HR changes in response to deep breathing (t = -2.72, p = 0.02) and to standing up (t = 
2.61, p = 0.03). Furthermore, in group NDHT there was a correlation between the BMI and 
the SBP changes in response to standing up (t = -2.39, p = 0.04). In group DHT, with a 
multiple linear regression test we found a correlation between age and the SBP changes in 
response to standing up (t = -3.19, p = 0.04).With a multiple linear regression test in group C, 
age correlated with the HR changes in response to deep breathing (t = -3.81, p = 0.02), while 
the BMI correlated with the SBP changes in response to standing up (t = 2.78, p = 0.01). 
Moreover, in group C, the SBP values correlated with the HR changes in response to deep 
breathing (t = 4.3, p = 0.01) and with the HR changes in response to the Valsalva manoeuvre 
(t = -4.48, p = 0.01). In the group C, the DBP values also correlated with the HR changes in 
response to the Valsalva manoeuvre (t = -3.68, p = 0.01). 
 
Table 13 Current perception thresholds in the first part of investigation. 
 Current perception threshold (mA) 
p  
Hz NDHT (n=18) DHT (n=10) C (n=11) 
Normal 
range 
M
ed
ia
n
 
n
er
v
e
 
2000 2.55±2.3 1.94±1.2 2.77±0.7 1.20-2.98 NS 
250 1.16±0.9 1.12±0.8 1.03±0.4 0.22-1.80 NS 
5 0.66±0.6 0.52±0.4 0.59±0.2 0.16-1.01 NS 
P
er
o
n
ea
l 
n
er
v
e
 
2000 3.06±2.8 3.46±3.2 3.38±0.8 1.87-5.16 NS 
250 2.38±2.9 2.22±2.8 1.51±0.7 0.46-1.90 NS 
5 1.24±1.7 1.74±2.9 0.73±0.3 0.18-1.70 NS 
 
   In group DHT, a positive correlation was found between the severity of CAN and the CPTs 
measured on the median nerve at 250 Hz (r = 0.69; p = 0.02) and 5 Hz (r = 0.74; p = 0.01). 
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   The SBP and DBP values did not correlate either with the severity of CAN or with the 
severity of PSN. We did not investigate heart rate variability. 
   The second part of investigation was planned to calculate BRS against CAN score. All the 
BRS values decreased after standing up in all groups, and they were highest in group C and 
lowest in group DHT (Table 14) All the patient groups were CAN positive (mean CAN 
scores: group C 1.0, group NDHT 3.64, group DHT 4.1). The CRT results are in Table 15. 
 
Table 14 The changes of baroreflex sensitivity (ms/mmHg) values in the second part of 
investigation. (
*
p < 0.05 standing vs. lying, 
†
p < 0.05 DHT vs. NDHT) 
 upBRSL downBRSL allBRSL upBRSS downBRSS allBRSS 
DHT 
(n=18) 
6.69±4.3 8.34±6.4 7.99±4.8 4.82±2.5* 4.43±2.4*† 4.42±1.8*† 
NDHT 
(n=22) 
9.87±5.3 9.7±6.5 10.04±5.0 6.69±4.3* 7.54±4.7 7.31±4.4* 
C (n=15) 10.31±6.1 9.98±4.6 10.93±4.2 5.64±2.3
* 
6.51±2.5* 6.13±2.3* 
 
Table 15 Results of cardiovascular reflex tests in the second part of investigation. (
*
p < 0.05 
NDHT vs. C and DHT vs. C) 
 C (n=15) NDHT (n=22) DHT (n=18) 
Deep breathing (beat/min) 20.0±7.1 15.35±6.3 13.17±6.2
* 
Valsalva manoeuvre 1.41±0.3 1.27±0.2 1.38±0.4
* 
30/15 ratio 1.18±0.5 1.1±0.3 1.18±0.2 
Standing up (mmHg) 8.73±4.0 15.55±13.13 21.6±11.34
* 
Sustained handgrip (mmHg) 24.67±9.7 18.73±8.1 14.56±8.9 
 
   In NDHT group there was a positive correlation between the 30/15 ratio and the upBRSS (r 
= 0.64, p = 0.0013), the downBRSS (r = 0.68, p = 0.0005) and the allBRSS (r = 0.65, p = 
0.0009). 
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4.2. Neurovascular decompression 
 
According to the MRA from the 50 patients no kind of NVPC was found in 6 cases. Left-
sided neurovascular contact was found in 43 cases, and right-sided contact in 1 case. Fifteen 
patients had type BS, 12 patients had type N and 17 had type D compression (Table 16). 
 
Table 16 Distribution of types of neurovascular pulsatile compression among all the 50 
patients by magnetic resonance investigation combined with angiography. Six patients had no 
NVPC. 
Type BS (n=15) Type N (n=12) Type D (n=17) 
BSL BSR BSB NL NR NB DL DR DB 
n=12 n=0 n=3 n=12 n=0 n=0 n=15 n=1 n=1 
 
   NVD was recommended for severe primary HT patients with neurovascular contacts only 
on the left side. In the cases of left-sided neurovascular contact with only mild-to-moderate 
increased BP level the NVD was not recommended. NVDs were performed on the 18 patients 
who agreed to surgery. Only 13 of these were patients of the Szeged 1st Department of 
Internal Medicine and the others were only sent for the surgical procedure from other 
hospitals, therefore data concerning them could not be collected retrospectively. All the 13 
patients (Table 17) followed up in the 1st Department of Internal Medicine came back to the 
visit month 1, 10 of them to the visit month 3, 10 of them to the visit month 6 and the same 9 
of them to the visit month 12 and 24. The two-year data of these 9 patients were analyzed, 
because they were the same at all visits (age: 43.7 ± 9.0 years, BMI: 28.5 ± 4.5 kg/m2, 
duration of HT: 14.2 ± 9.3 years). 
   In the 1st Department of Internal Medicine NVD was recommended not just in a case of 
severe HT but a positive family history of fatal or non-fatal cardio-/cerebrovascular 
complications was also required. Of course all possible secondary causes were excluded in all 
cases prior to MRA. 
   Only in 7 non-operated cases the follow-up was continuous and could be collected the 24 
monthly data (age: 40.0 ± 19.3 years, BMI: 29.4 ± 5.5 kg/m2, duration of HT: 6.1 ± 7.3 years). 
Many of the remaining 25 non-operated patients did not come back to visits at all or just 
irregularly. Five operated patients were only sent for NVD from different hospitals and 
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outpatient clinics, 2 operated patients did not come back to visits at all and 2 operated patients 
only a few times. In this retrospective work I did not investigate the history of these patients. 
Further I did not investigate why the patients did not come back to visits. 
 
Table 17 Data of 13 operated patients. 
Gender 
Age 
(years) 
Time 
of HT 
(years) 
BMI 
(kg/m2) 
BP before 
NVD 
(mmHg) 
BP after 
NVD 
(mmHg) 
PP 
before 
NVD 
(mmHg) 
PP   
after 
NVD 
(mmHg) 
No of 
comb. 
before 
NVD 
No of 
comb. 
after NVD 
F 52 16 29.9 190/120 156/100 70 56 8 4 
F 45 5 26.5 220/125 150/80 95 50 4 3 
M 50 5 29.0 190/105 130/75 85 55 5 5 
M 31 18 23.1 210/100 130/80 110 50 4 4 
F 47 15 22.8 280/150 140/80 130 60 6 3 
M 53 15 29.4 240/150 120/80 90 40 3 1 
F 47 12 no data 240/145 145/90 95 55 6 4 
F 40 10 35.4 200/120 170/120 80 50 6 5 
F 35 5 33.6 160/100 140/90 60 50 6 4 
F 33 13 22.0 300/140 143/92 160 51 4 4 
F 55 35 27.1 200/110 154/90 90 64 7 5 
F 50 17 28.9 200/100 120/80 100 40 7 4 
F 34 14 25.5 200/140 140/80 140 60 4 4 
 
   In the course of the 18 NVD procedures, the MRA findings were confirmed in all but one 
case using the neurosurgical database. In this case, the MRA indicated NVPC of the root-
entry zone of cranial nerves IX and X and of the RVLM caused by the PICA and the VA on 
the left side. However, NVD revealed only NVPC of the RVLM caused by the VA. 
   Among the 7 non-operated patients, the MRA pointed to NVPC of the RVLM in 4 cases 
and of the root-entry zone of cranial nerves IX and X in 3 cases, all on the left side. In these 
cases there were no double contacts. 
   Both the SBP and the DBP levels were significantly higher in the operated group before the 
NVD, as did the PP and all decreased significantly after the NVD. Although there were mild 
increases in BP during the 2 years, they remained below the BP levels recorded before the 
NVD (Tables 18 and 19). In the non-operated group, the BP did not change significantly 
during the 2 years (Table 18). 
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Table 18 The systolic, the diastolic blood pressure and the number of antihypertensive agents 
during the 2 years. (*p < 0.05 vs. the preoperative level, **p < 0.05 non-operated vs. operated) 
 
 
At 
operation or 
MRA 
Month 1 Month 3 Month 6 Month 12 Month 24 
Non- 
operated 
(n=7) 
SBP 
(mmHg) 
156±36** 141±22 161±32 151±37 158±34 142±26 
DBP 
(mmHg) 
85±24** 87±15 96±21 85±21 85±24 76±15 
№ of 
agents 
4.3±2.6 5.1±2.3 5.1±2.3 5.3±2.4 5.1±2.3 5.1±2.3 
Operated 
(n=9) 
SBP 
(mmHg) 
211±40 147±13* 153±18* 161±21* 152±29* 148±32* 
DBP 
(mmHg) 
116±17 91±13* 99±15 97±13 94±11* 95±18 
№ of 
agents 
5.9±1.4 4.7±0.9* 5.0±1.1 5.2±1.1 5.4±0.9 5.7±1.0 
 
    The significance of differences of mean BP values before and after the NVD only derived 
from the significant differences observed in group DL. The decreases of BP were not 
statistically significant in other groups and subgroups (Table 20). 
   All the NVDs were successful, no serious complications or death connected with it, were 
observed. Only transient vertigo appeared in some cases after the decrease of BP levels. 
   No correlation was found between either the types of NVD and the pressure or the number 
of antihypertensive agents. However the change of BP after NVD was only significant in 
cases of dual NVPC on the left side. The absolute BP values of these patients did not differ 
significantly from the others. 
   The need for the antihypertensive medication was calculated as the sum of the number of 
different drugs administered. It also decreased in most of the cases after NVD (Table 21). 
   The type D NVPC was observed most frequently among the 13 operated patients, 6 of them 
on the left side and 1 on both sides. However in the latter case NVD was performed only on 
the left side (Table 22).  
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Table 19 The blood pressure of the operated patients during the 2 years. 
 
 
At 
operation  
Month 1 Month 3 Month 6 Month 12 Month 24 
Patient 1 
SBP 
(mmHg) 
190 156 156 185 165 160 
DBP 
(mmHg) 
120 100 100 108 96 110 
Patient 2 
SBP 
(mmHg) 
190 130 153 142 124 140 
DBP 
(mmHg) 
105 75 109 99 89 100 
Patient 3 
SBP 
(mmHg) 
210 130 160 138 130 112 
DBP 
(mmHg) 
100 80 110 80 100 80 
Patient 4 
SBP 
(mmHg) 
240 145 160 146 150 155 
DBP 
(mmHg) 
145 90 90 92 90 100 
Patient 5 
SBP 
(mmHg) 
200 170 180 200 220 220 
DBP 
(mmHg) 
120 120 130 120 120 130 
Patient 6 
SBP 
(mmHg) 
160 140 130 150 130 110 
DBP 
(mmHg) 
100 90 80 90 80 70 
Patient 7 
SBP 
(mmHg) 
300 143 122 170 145 139 
DBP 
(mmHg) 
140 92 87 90 88 81 
Patient 8 
SBP 
(mmHg) 
200 154 150 148 151 148 
DBP 
(mmHg) 
110 90 92 88 89 95 
Patient 9 
SBP 
(mmHg) 
200 158 165 168 150 148 
DBP 
(mmHg) 
100 80 95 108 90 95 
 
   In the case of a 57-year-old white woman with RHT, the MRA showed mild compression 
on the left anterior surface of the RVLM at the level of the PICA. In June 2009, neurosurgical 
NVD was performed under anaesthesia. A tissue-friendly haemostatic sponge was placed 
between the cranial nerves and the PICA.  
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Table 20 Blood pressure and pulse pressure values in operated patients by neurovascular 
pulsatile compression subgroups. (*p < 0.05 after vs. before; **p < 0.01 after vs. before) 
 
SBP (mmHg) DBP (mmHg) PP (mmHg) 
Before 
NVD 
After  
NVD 
Before 
NVD 
After 
NVD 
Before 
NVD 
After  
NVD 
DL 20111 **1375 1167 *874 857 *502 
BSL 24040 1477 13020 855 11020 622 
NL 22550 14321 12519 9319 10043 508 
DB 240 145 145 90 95 55 
 
Table 21 The number of drugs in combination of the operated patients during the 2 years. 
 Number of drugs in combination 
At 
operation 
(n=13) 
Month 1 
(n=13) 
Month 3 
(n=10) 
Month 6 
(n=10) 
Month 12 
(n=9) 
Month 24 
(n=9) 
Patient 1 8 4 5 6 6 7 
Patient 2 5 6 6 6 5 5 
Patient 3 4 6 3 4 4 4 
Patient 4 6 4 5 4 5 6 
Patient 5 6 5 5 5 6 6 
Patient 6 6 4 4 4 5 5 
Patient 7 4 4 5 5 5 5 
Patient 8 7 5 7 7 7 7 
Patient 9 7 4 5 6 6 6 
 
Table 22 Distribution of types of neurovascular pulsatile compression among the operated 13 
patients. 
Type BS (n=2) Type N (n=4) Type D (n=7) 
BSL BSR BSB NL NR NB DL DR DB 
n=2 n=0 n=0 n=4 n=0 n=0 n=6 n=0 n=1 
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   During the NVD procedure, the MRA finding was confirmed. NVD was successful, and no 
serious complications of the intervention were observed. Both SBP and DBP decreased after 
NVD, as measured with the ABPM-04. During the active period, the mean BP was 163/73 
mmHg before and 115/62 mmHg after NVD. During the passive period, the mean BP was 
130/60 mmHg before and 113/50 mmHg after NVD. The hyperbaric time index decreased 
from 76.63/7.61% to 8.47/0.0%. Less antihypertensive medication was needed within a short 
period after NVD; only five different drugs were needed from approximately postoperative 
day 8 (Table 23). 
 
Table 23 The change of the antihypertensive therapy before and after the neurovascular 
decompression. 
Before NVD After NVD 
• dihydralazine 0-3-2-1 tab. 
• doxazosin 4 mg 2x1 tab. 
• metoprolol 50 mg 2x1/2 tab. 
• indapamide at lunch 1 tab. 
• urapidil 90 mg 3x1 cap. 
• guanfacine2x1 tab. 
• isosorbid mononitrate 60 mg at 
morning 1 caps. 
• amlodipine 5 mg 2x1,5 tab. 
• losartan 100 mg 2x1 tab. 
• moxonidine 0.4 mg 0-1-1 tab. 
 
• metoprolol 50 mg 2x1/2 tab. 
• indapamide at lunch 1 tab. 
• isosorbid mononitrate 60 mg at 
morning 1 caps. 
• amlodipine 5 mg 2x1 tab. 
• losartan 50 mg ½-0-1 tab. 
 
 
   Normally, the spontaneous BRS decreases after standing up, and this dynamic was also 
preserved after NVD. In the supine position, the BRS was 5.62 ms/mmHg before and 7.51 
ms/mmHg after NVD. In the standing position, the BRS was 3.29 ms/mmHg before and 5.57 
ms/mmHg after NVD. The BRS increased after NVD in both positions.  
   The sum of the CAN scores did not change; it remained 3. However, the decrease in BP 
after standing up decreased to half of the value detected before NVD (Table 24). 
   The plasma NE level decreased to almost half of the level measured before NVD (421 
pg/ml vs. 282 pg/ml, before vs. after). 
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Table 24 Changes of the cardiac autonomic neuropathy before and after neurovascular 
decompression. 
 Change of 
HR 
(beat/min) 
Valsalva 
ratio 
30/15 
ratio  
Test 
Handgrip 
(mmHg) 
Orthostatic 
hypotension 
(mmHg) 
CAN 
score  
Before 
NVD 
19 1.66 1.03 35 46 3 
After 
NVD 
15 1.21 0.97 20 23.14 3 
 
 
4.3. Transcatheter renal denervation 
 
Both the SBP and the DBP decreased in all cases after the RDN. The changes of mean BP 
values after the successful RDN are summarized in Table 25. 
 
Table 25 Characteristics of renal denervations and changes of blood pressure after renal 
denervations in four resistant hypertensive patients. 
Patients 
52-year old 
woman 
50-year old 
woman 
39-year old 
woman 
62-year old 
man 
N of ablation 
sites (right) 
5 5 5 5 
N of ablation 
sites (left) 
6 5 5 5 
Complications 
post-procedure 
headache, vomiting 
no no no 
BP (mmHg) 
prior to RDN 
204/105 183/111 161/92 166/104 
BP (mmHg) 
after RDN 
111/50 160/95 134/77 132/83 
BP (mmHg) 1 
month later 
156/73 177/101 140/84 119/72 
Anti-HT 
therapy change 
after RDN 
2 stopped 
2 elevated 
2 elevated 
3 decreased 
4 stopped,  
1 decreased 
3 stopped  
4 decreased  
 
   BRS was calculated only in the case of the 52-year old woman (Table 26). Unfortunately 
ECG and BP data recordings were unsuccessful in other cases because of finger cuff failure of 
the Finometer device.  
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Table 26 Changes of baroreflex sensitivity after renal denervation in a 52-year old woman. 
 upBRSL 
(ms/mmHg) 
upBRSS 
(ms/mmHg) 
downBRSL 
(ms/mmHg) 
downBRSS 
(ms/mmHg) 
allBRSL 
(ms/mmHg) 
allBRSS 
(ms/mmHg) 
Before 
RDN 
3.21 2.53 3.53 2.31 3.36 2.65 
After 
RDN 
11.26 5.05 5.48 4.48 8.69 4.85 
 
 
5. DISCUSSION 
 
In severe diabetic CAN characterized by CRTs, the 5-year mortality exceeds 50%; more than 
half of these cases were cardiac (86). In a meta-analysis, the mortality of diabetics with CAN 
after 5.8 years was 29%, whereas for diabetics without CAN the mortality was just 6% (95). 
   In diabetic patients with CAN, the parasympathetic dysfunction appears first and is 
associated with sympathetic overactivity, especially during the night. An increase in the 
sympathetic activity and/or a decrease in the parasympathetic tone encourage the development 
of malignant ventricular arrhythmias (96). In diabetic patients with parasympathetic CAN, the 
orthostatic hypotension is less expressed because of the sympathetic overactivity (97). 
Mostly, the response to the handgrip-test from the sympathetic CRTs is abnormal (97). In our 
study among the sympathetic CRTs the response to the handgrip-test was mostly abnormal in 
both HT groups. The SBP changes in response to standing up were generally borderline and 
only in a few cases abnormal. We did not find any relationship between the basic SBP and the 
SBP changes in response to standing up. From our data, there is a connection between the 
duration of the HT and the severity of autonomic neuropathy. Although most of the 
hypertensive patients displayed sympathetic and parasympathetic neuropathies, the 
parasympathetic dysfunctions (38.1%) predominated over the sympathetic dysfunctions 
(21.43%).  
   It is well known that effective BP control reduces the cardiovascular risk in diabetic and 
nondiabetic hypertensive patients (35, 98, 99). In our study, DM associated with HT did not 
enhance the prevalence of neural dysfunctions, and the two HT groups did not differ 
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significantly in BP values. These data might suggest that the effective BP control might have 
contributed to the lack of difference in the severity of neuropathy between the two patient 
groups. Interestingly, in the diabetic group, the extent of hypaesthesia of the small fibres 
correlated positively with the severity of the CAN on the upper extremities. Moreover, in the 
diabetic group, there was a positive correlation between the severity of hypaesthesia of the 
small fibres on the lower extremities and the documented duration of DM and HT. In the 
NDHT group, we found an association between the orthostatic hypotension and the 
hypaesthesia of the large and the small fibres on the lower extremities. In the diabetic group, 
there was a negative correlation between the HR changes in response to standing up and the 
hypaesthesia of the large and the small fibres on the lower extremities. These observations 
might indicate that vascular factors may play a role in the development of PSN. Our 
observation that all the CPTs of the CAN-free patients were within the normal range might 
confirm the association between the autonomic and peripheral sensory neuropathy. 
   The association between the duration of diabetes and the presence of diabetic peripheral 
neuropathy has already been described (40), and is also supported by our data. Furthermore, 
we found correlation between the duration of HT and the severity of autonomic and peripheral 
sensory neuropathy. There are some limitations to this study. This is a small study with a low 
number of enrolled patients. The potential effect of the antihypertensive medication on the 
autonomic function cannot be excluded completely, but it is unlikely because there was no 
significant difference between the antihypertensive medications of the treated groups. 
Furthermore, some of the agents amend while some of them worsen the autonomic function.  
   The sympathetic nervous system may produce selective changes in efferent outflow to 
different organs. The output to different sympathetic preganglionic neurons depends on the 
central autonomic nervous system organization including relative contributions of a wide 
range of brain nuclei and on the inputs to those nuclei (from baroreceptors, chemoreceptors, 
somatic receptors and from all areas of the brain). Although in RHT the SNA is increased the 
sympatholytic drug therapy, usually in a multiple combination, is not enough to reach the goal 
BP. 
   The cranial nerve IX carries afferent signals from the aortic arch, whereas cranial nerve X 
does so from the carotid sinus. The left nerve X also carries afferent signals from the 
mechanoreceptors in the left atrial wall (10). The sympathico-excitatory catecholamine 
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synthesizing C1 neurons are situated in the RVLM, probably 1 mm below the surface of the 
brain stem. These catecholaminergic C1 neurons have an important role in maintaining 
resting sympathetic vasomotor tone and arterial HT. Efferent fibres lead from there into the 
preganglionic sympathetic neurons located in the intermediolateral column of the thoracic 
spinal cord. The discharge of these neurons increases the SNA (12). Stimulation of the C1 
neurons with glutamate elevates the BP, whereas cooling or destruction of this region 
decreases the BP, as does stimulation with gamma-amino butyric acid (13, 100, 101). 
   The NVPC at the root-entry zone of cranial nerves IX and X can cause a temporary oxygen 
deficiency, which blocks signal transmission into the NTS. Therefore it will not be activated 
and the C1 neurons released from the physiological inhibition caused by the NTS (101). 
According to another theory, direct excitation of the C1 neurons by arterial pulsation can 
surpass the inhibitory signals from the NTS, causing a permanent discharge of the excitatory 
neurons (102). 
   Microanatomical investigations performed by Naraghi et al. of samples from cadavers of 
HT patients did not reveal either demyelinization or degeneration provoked by NVPC (101). 
In that work they described 3 types of NVPC: type I (monovascular): compression by only the 
VA or only the PICA; type II (vertebral): compression by only the VA; and type III 
(combination): compression by both the VA and the PICA. Our grouping was similar to 
theirs. 
   In a recent Japanese study it has been reported, similar to many previous studies, that 
prevalence of NVPC of the RVLM was significantly higher in the group of patients with 
primary HT (35%) than in the normotensive group (13%) (p < 0.05) (100, 101, 102-106). A 
recent study using high-resolution MRI scans with 1 mm slices showed that the frequency of 
NVPC of the RVLM was clearly and significantly higher in patients with primary HT 
(73.5%) than in patients with secondary HT (12.5%) (107).  
   Since Jannetta’s papers many studies have confirmed that an NVD of the RVLM on the left 
side decreases the BP value, even lasting for many years (10, 13, 108, 109). Among others 
Sasaki et al. reported successful NVD in cases of 4 refractory HT patients (110). Three of 
them had hemifacial spasm. Our patients did not show any symptoms of cranial rhizopathies. 
In a previous work we described that 2 years after a successful NVD the BP values and the 
therapeutic efforts were decreased compared to the pre-operative period (111). 
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   In primary HT patients with NVPC on the left side of the RVLM there is a significantly 
increased plasma NE level confirming the elevated SNA (88, 89). More evidence for 
increased SNA is the increased muscle SNA in primary HT patients with NVPC of the 
RVLM (112). 
   German authors have presented their results of 14 HT patients with more than 3 
antihypertensive drugs who underwent NVD procedure. Not only the BP but also SNA 
decreased after NVD (113). 
   A Japanese team have reported a case of a patient, with RHT and NVPC of the RVLM on 
the left side, who experienced notable BP reduction by clonidine therapy (114). However, 
unfortunately not all the NVPC HT patients react to central-acting antihypertensive agents; 
otherwise discussion about a possible beneficial neurosurgical procedure would not be 
necessary.  
   It is still not clear why NVPC only on the left side causes HT, and does not on the right 
side, though some study groups have reported NVPC with the same frequency on both sides 
(101, 106). 
   According to the literature NVD is usually performed in HT patients with at least 3 different 
antihypertensive drugs. In our cases the mean number of antihypertensive agents were 5. 
   The lower plasma NE level and higher BRS values after NVD confirm that there is a 
sympathetic overactivity in RVLM pulsatile compression. The efficacy of NVD confirms that 
C1 neurons may have an important role in the maintenance of this sympathetic overactivity. 
After NVD, the repetitive discharge of C1 neurons was halted. As a part of CAN, the degree 
of orthostatic hypotension decreased, which can also be explained by the improvement in 
short-term CV regulation. In this case, after NVD, the BRS, BP and the need for 
antihypertensive medication also improved. 
   The slightly elevation of the BP levels and the increase of the need for antihypertensive 
therapy may be caused by the target organ damage of HT. The NVD may be most beneficial 
if both the BP levels and the medication also decrease after it, but it is still beneficial if the BP 
levels decrease with sustained or just slightly improved need for antihypertensive medication. 
   Non-selective surgical sympathectomy/denervation was effectively used to decrease the BP 
in severe hypertension before antihypertensive drugs became generally available. But 
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unfortunately side effects arising from the non-selective aspect significantly worsened the 
quality of life of HT patients (79, 80, 81). 
   Development of endovascular catheter technology enables selective denervation of the 
kidney, with radiofrequency energy delivered in the renal artery lumen, accessing the renal 
nerves located in the adventitia of arteries. The first-in-man, non-randomized cohort of 
patients with RHT (SBP ≥160 mm Hg on ≥3 anti-HT drugs, including a diuretic; eGFR ≥ 45 
ml/min) was published by Krum et al. in 2009. In five centers 45 RDNs were performed and 
the mean BP decrease was -27/-17 mm Hg by the end of 12 months follow-up (94).  
   This cohort was expanded in the Symplicity HTN-1 trial. This was a multicentre safety and 
proof-of-principle cohort with 153 RHT patients. The mean baseline BP was 176/98 ± 17/15 
mmHg, and the mean number of antihypertensive drugs were 5.0 ± 1.4. Bilateral RDN were 
performed in all cases. No major complications were observed and only 4 minors ones: 1 
renal artery dissection during catheter delivery (prior to RF energy) and access site 
complications. One, 3, 6, 12 and 24 months after the RDN the BP values were decreased by 
20/10, 24/11, 25/11, 23/11, 26/14 and 32/14 mmHg in order (115).  
   After it a multicenter, randomized, controlled clinical trial was planned named Symplicity 
HTN-2. RDN was performed in cases of 52 RHT patients with mean baseline BP 178/96 
mmHg and more than 3 antihypertensive medications. The BP reduction was 20/7, 24/8 and 
32/12 mmHg in order 1, 3 and 6 months after RDN. No serious device or procedure related 
adverse events were observed. The 6-month renal imaging showed no vascular abnormality at 
any RDN treatment site (82).  
   The RDN reduces the sympathetic activity in OSAS (116), the insulin resistance (117), the 
plasma renin activity, the left ventricular mass and improves the renal blood flow and the 
BRS (118). 
   All the RDNs were technically successful in this observation and BP values also decreased. 
Although the reduction of antihypertensive medication was not the objective of any RDN 
treatment, in all cases in this work the medication decreased by 1 or 2 drugs. Of course it is a 
very important aspect of improving the adherence and compliance of patients. In the case of a 
52-year old woman after the RDN the BRS increased both in lying and standing position. 
More mechanisms could explain this improvement of BRS. One is the decrease of SNA, but 
perhaps as independent factors the decrease of BP or the arterial stiffness may resulted in 
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increase of BRS. From a decrease of SNA decreased CV morbidity and mortality could be 
expected as a long-term conclusion.  
 
 
6. SUMMARY 
 
In the first study reported in this thesis we hypothesized that the complications generally 
attributed to DM only may also appear in NDHT. In our work both CAN and PSN could be 
observed together in NDHT and their severity did not differ significantly from that in DHT. It 
may further support the view that vascular factors may play an essential role in the 
development of neuropathy. The duration of the HT rather than the BP values themselves 
might be an important risk factor for the development of autonomic and peripheral sensory 
neural dysfunctions. Our results provide further support for parasympathetic dysfunction 
enhancing SNA in HT and DM. The BRS decreased in both lying and standing positions in 
diabetic and nondiabetic HT groups, but it was lowest in the diabetic group, supporting the 
idea that DM and HT together may multiply the CV risk. Our results may suggest that poorly 
healing ulcers of the lower extremities, due to microvascular complications and often leading 
to amputation based on PSN, threaten not only diabetic patients but also NDHT. These 
observations might be essential for the development of risk reduction strategies among NDHT 
to avoid or postpone the development of neuropathy. 
   In the second work of this thesis we collected retrospective data about invasive treatment 
methods of RHT, focusing on NVD of the brain stem. In the cases of severe primary RHT, 
without any possible so-called conventional secondary causes, not responding to multiple 
combinations of therapy, NVPC of the brain stem should be considered and MRA performed. 
If NVPC is confirmed by MRA, successful neurosurgical NVD of the brain stem on the left 
side can guarantee a BP reduction with less or same need for antihypertensive medication. 
From our results NVPCs on the left side of the brain stem may relate to HT, but the type of 
the NVPC does not correlate with the BP values. Therefore, perhaps, neither the location nor 
the number of NVPCs on the left side affects the degree of the SNA. From this point of view 
the fact of NVPC on the left side is the most important not its type. A continuous pulsatile 
stimulation of the RVLM on the left side may lead to a tonic increase in SNA and HT, but it 
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cannot explain all the refractory HTs. A new question arises here: if NVD may affect the BP 
and the SNA, is it really a case of a primary HT or is it a case of an unconventional secondary 
form? More data are needed to decide this. Further, our results – MRA findings compared to 
intraoperative observations - may confirm that MRA slice thickness 1 mm is necessary for 
successful identification of an NVPC.  
   Before any invasive treatment of RHT the pseudoresistant HT, the "white-coat effect", the 
conventional secondary causes and other patient- and/or therapy-related causes should be 
excluded. After confirming the primary RHT it is important to optimize the medical 
antihypertensive treatment. Is RDN the appropriate next step? If the office BP is sustained 
>160/ mmHg with eGFR >45 ml/min/1.73 m
2
 and the anatomy of renal artery is suitable then 
the answer is "yes". Compared to NVD, the RDN is an easier invasive technique with fewer 
possible side effects and a shorter procedure time.  
 
 
7. CONCLUSIONS (NEW OBSERVATIONS) 
 
 There is an increased sympathetic nerve activity in hypertension not just because of 
the pathogenesis of primary hypertension, but because of parasympathetic dysfunction 
based on possible microvascular complications. 
 
 Peripheral sensory neuropathy also can be observed in hypertension without diabetes 
mellitus. 
 
 In resistant hypertension a neurovascular pulsatile compression of the brain stem on 
the left side may cause sustained sympathetic overactivity leading to increased blood 
pressure.  
 
 At least 1 mm MRA slice thickness is required to indentify the possible neurovascular 
contacts. 
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 In resistant hypertension with neurovascular pulsatile compression of the brain stem 
on the left side a neurovascular decompression may be prescribed because 
subsequently the arterial systolic and diastolic blood pressure and sympathetic nerve 
activity may decrease permanently. 
 
 The baseline blood pressure is independent of the type of the neurovascular pulsatile 
compression of the brain stem on the left side, but in a case of double compression on 
the left side after a decompression there is a bigger reduction of blood pressure.  
 
 The transcatheter renal radiofrequency denervation may lead to a significant decrease 
of blood pressure and sympathetic nerve activity.  
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